The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignancies dispayed moderate cytoplasmic and nuclear immunoreactivity. Colorectal and gastric cancers displayed strong cytoplasmic staining with additional membranous positivity while cases of malignant gliomas and lymphomas showed strong cytoplasmic positivity.
A majority of malignant cells displayed moderate cytoplasmic immunoreactivity. Several urothelial cancers were strongly stained, while most malignant gliomas were weakly stained or negative.
Malignant cells generally displayed weak to moderate immunoreactivity. Several cases of malignant lymphomas, urothelial, gastric and breast cancers showed strong cytoplasmic staining while colorectal cancers displayed additional strong membranous immunoreactivity. Malignant gliomas, skin, lung and liver cancers were negative or weakly stained.
Most of the malignant tissues displayed moderate to strong cytoplasmic and/or membranous positivity. Malignant gliomas and prostate cancers were negative in a majority of cases while many malignant melanomas, skin and testicular cancers were weakly stained or negative.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
